Filing Alert: Finch Therapeutics Chapter 11
Finch Therapeutics Group, Inc., a Boston, MA-based microbiome therapeutics company, filed for Chapter 11 protection on March 22, 2026, in the U.S. Bankruptcy...
Finch Therapeutics Group, Inc. and its debtor affiliates⁽¹⁾, a Boston, MA-based microbiome therapeutics company, filed for Chapter 11 protection on Mar. 22 in the U.S. Bankruptcy Court for the District of Delaware.
Debtor's affiliate Finch Therapeutics, Inc. reports $10 million in assets to $50 million in liabilities.
The company reports $1 million to $10 million in assets and $0 to $50 thousand (affiliates report liabilities of up to $10 million to $50 million) in liabilities. The filing indicates that there will be funds available for distribution to unsecured creditors. The case number is 26-10409.
⁽¹⁾ For a complete list of debtor entities, see the Chapter 11 Debtors table.
Chapter 11 Debtors
Top Unsecured Claims
Key Parties
Counsel:
- Robert A. Weber
Chipman Brown Cicero & Cole, LLP
Email: weber@chipmanbrown.com
Bankruptcy Counsel:
- Ropes & Gray LLP
Investment Banker:
- Rock Creek Advisors
Signatories:
- Matthew P. Blischak – Chief Executive Officer
Claims Agent:
Equity Security Holders:
- Crestovo Investor LLC – 24.7% Equity Interest
- Symbiosis LLC – 10% Equity Interest
- Great Point Capital LLC – 7.5% Equity Interest
- Other Minority Holders – 57.8% Equity Interest